Major cancer trial aims to boost surgery success with powerful new drug combo
NCT ID NCT06952621
Summary
This study is testing whether a new combination of drugs given before surgery works better than the current standard treatment for advanced esophageal cancer. About 390 patients with operable cancer will be randomly assigned to receive either the new treatment (toripalimab plus chemotherapy) or the standard chemotherapy. The main goal is to see if the new approach helps more patients achieve a complete disappearance of cancer cells in the surgically removed tissue.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospitial, Xi'an, Shaanxi Rrovince
Xi'an, Shaanxi, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.